Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse til evaluering af effekt, sikkerhed, farmakokinetik og farmakodynamik af ocrelizumab hos deltagere med relapserende multipel sklerose og primær progressiv multipel sklerose

29. september 2026 opdateret af: Hoffmann-La Roche

Et multicenter, åbent, en-armet studie til evaluering af effekt, sikkerhed, farmakokinetik og farmakodynamik af ocrelizumab hos kinesiske patienter med recidiverende multipel sklerose og primær progressiv multipel sklerose

The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Beijing, Kina, 100034
        • Peking University First Hospital
      • Beijing, Kina, 100032
        • Peking Union Medical College Hospital
      • Beijing, Kina, 100730
        • Beijing Hospital of Ministry of Health
      • Changsha, Kina, 410008
        • Xiangya Hospital Central South University
      • Chengdu, Kina, 610041
        • West China Hospital of Sichuan University
      • Chongqing, Kina, 400016
        • The First Affiliated Hospital, Chongqing Medical University
      • Guangzhou, Kina, 510080
        • The First Affiliated Hospital of Sun Yat-sen University
      • Guangzhou, Kina, 510630
        • The Third Affiliated Hospital of Sun Yat-Sen University
      • Hangzhou, Kina, 310003
        • The First Affiliated Hospital of College of Medicine, Zhejiang University
      • Hohhot, Kina, 010011
        • Inner Mongolia Autonomous Region People's Hospital
      • Lanzhou, Kina, 730030
        • Lanzhou University Second Hospital
      • Shenyang, Kina, DUMMY_VALUE
        • The First Hospital of China Medical University
      • Shijiazhuang, Kina, 050000
        • The Second Hospital of Hebei Medical University
      • Taiyuan, Kina, 030000
        • 1st Affiliated Hospital of Shanxi Medical University
      • Wuhan, Kina, 430030
        • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
      • Ürümqi, Kina, 830000
        • Xinjiang People Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330209
        • The First Affiliated Hospital of Nanchang University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
  • EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
  • Documented MRI of brain with abnormalities consistent with MS before screening

Exclusion Criteria:

  • Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
  • History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
  • Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
  • History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
  • Inability to complete an MRI scan or contraindication to Gd administration
  • Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
  • Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
  • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
  • Known history of human immunodeficiency virus (HIV) infection
  • Lack of peripheral venous access
  • Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
  • Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: RMS Cohort

Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks).

Ocrelizumab will be administered as per the schedule specified in the respective arms.

Andre navne:
  • RO4964913
  • OCREVUS®
Eksperimentel: PPMS Cohort

Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks).

Ocrelizumab will be administered as per the schedule specified in the respective arms.

Andre navne:
  • RO4964913
  • OCREVUS®

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
RMS-kohorte: Årlig protokoldefineret recidivrate
Tidsramme: Op til cirka 1,6 år
Op til cirka 1,6 år
PPMS-kohorte: B-celleniveauer i blod
Tidsramme: Op til uge 48
Op til uge 48
PPMS-kohorte: Procentdel af deltagere, der opnår Cluster of Differentiation 19 (CD19+) B-celle-niveauer på <10 celler/mikroliter (μL) ved uge 48
Tidsramme: Ved uge 48
Ved uge 48

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
RMS-kohorte: Procentdel af deltagere uden tegn på sygdomsaktivitet (NEDA3) i en 48-ugers periode
Tidsramme: Op til uge 48
Op til uge 48
RMS-kohorte: Procentdel af recidivfrie deltagere efter uge 48
Tidsramme: Op til uge 48
Op til uge 48
RMS-kohorte: Procentdel af deltagere, der har NEDA3 i en 24-ugers periode
Tidsramme: Op til uge 24
Op til uge 24
RMS-kohorte: Samlet antal T1 gadolinium (Gd)-forstærkende læsioner påvist ved hjerne-magnetisk resonans (MRI)
Tidsramme: Op til uge 48
Op til uge 48
RMS-kohorte: Samlet antal nye eller forstørrede T2-hyperintense læsioner som påvist ved hjerne-MRI
Tidsramme: Op til uge 48
Op til uge 48
RMS- og PPMS-kohorter: Ændring fra baseline til uge 48 i koncentrationen af serum neurofilament lys kæde (NfL)
Tidsramme: Baseline op til uge 48
Baseline op til uge 48
RMS og PPMS-kohorter: Serumkoncentration af Ocrelizumab
Tidsramme: Op til uge 48
Op til uge 48
RMS-kohorte: B-celleniveauer i blod
Tidsramme: Op til uge 48
Op til uge 48
RMS-kohorte: Procentdel af deltagere, der opnår CD19+ B-celle-niveauer på <10 celler/μL i uge 48
Tidsramme: Ved uge 48
Ved uge 48
PPMS-kohorte: Samlet antal T1 Gd-forstærkende læsioner som detekteret af hjerne-MRI ved uge 24 og uge 48
Tidsramme: Uge 24 og Uge 48
Uge 24 og Uge 48
PPMS-kohorte: Samlet antal nye eller forstørrede T2-hyperintense læsioner, som detekteres ved hjerne-MR ved uge 24 og uge 48
Tidsramme: Uge 24 og Uge 48
Uge 24 og Uge 48
RMS- og PPMS-kohorter: Antal deltagere med bivirkninger (AEs)
Tidsramme: Op til cirka 1,8 år
Op til cirka 1,8 år
RMS- og PPMS-kohorter: Ændring fra baseline i T-celleniveau
Tidsramme: Op til cirka 1,8 år
Op til cirka 1,8 år
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
Tidsramme: Baseline up to Week 48

EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability.

Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
Tidsramme: Baseline up to Week 48

The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful.

Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
Tidsramme: Baseline up to Week 48

The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful.

Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
Tidsramme: Baseline, Week 48

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

Baseline, Week 48
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Up to approximately 1.8 years

C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior.

Up to approximately 1.8 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Clinical Trials, Hoffmann-La Roche

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

4. juli 2025

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

16. marts 2026

Først indsendt, der opfyldte QC-kriterier

16. marts 2026

Først opslået (Faktiske)

19. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner